-
1.SOLUBILITY-ENHANCED PHARMACEUTICAL COMPOSITIONS COMPRISING ZAFIRLUKAST 审中-公开
标题翻译: 包含ZAFIRLUKAST的溶解性增强药物组合物公开(公告)号:US20090012146A1
公开(公告)日:2009-01-08
申请号:US12166493
申请日:2008-07-02
申请人: Giridhar Reddy Buggana , Srikanth Basety , Rahul Sudhakar Gawande , Ravinder Kodipyaka , Srinivas Irukulla , Indu Bhushan , Mailatur Sivaraman Mohan , Praveen Kumar Bembaloor
发明人: Giridhar Reddy Buggana , Srikanth Basety , Rahul Sudhakar Gawande , Ravinder Kodipyaka , Srinivas Irukulla , Indu Bhushan , Mailatur Sivaraman Mohan , Praveen Kumar Bembaloor
IPC分类号: A61K31/404 , A61P11/06
CPC分类号: A61K9/146 , A61K9/145 , A61K9/1623 , A61K9/1652
摘要: Stable pharmaceutical compositions comprising zafirlukast and pharmaceutically acceptable salts, solvates, polymorphs, enantiomers or mixtures thereof, together with one or more pharmaceutically acceptable polymers, and processes for their preparation.
摘要翻译: 包含扎非司酮及其药学上可接受的盐,溶剂化物,多晶型物,对映体或其混合物以及一种或多种药学上可接受的聚合物的稳定的药物组合物,及其制备方法。
-
公开(公告)号:US20100183710A1
公开(公告)日:2010-07-22
申请号:US11994943
申请日:2006-07-07
申请人: Vijayabhaskar Bolugoddu , Jaydeepkumar Dahyabhai Lilakar , Ramchandra Reddy Pingili , Swarupa Reddy Dudipala , Adolf Ceasor Goldwyn , Bala Murali Krishna Pittala , Mailatur Sivaraman Mohan , Indu Bhushan , Ravinder Kodipyaka , Rahul Sudhakar Gawande , Srikanth Basety
发明人: Vijayabhaskar Bolugoddu , Jaydeepkumar Dahyabhai Lilakar , Ramchandra Reddy Pingili , Swarupa Reddy Dudipala , Adolf Ceasor Goldwyn , Bala Murali Krishna Pittala , Mailatur Sivaraman Mohan , Indu Bhushan , Ravinder Kodipyaka , Rahul Sudhakar Gawande , Srikanth Basety
IPC分类号: A61K9/64 , C07D401/12 , A61K31/4439 , A61K9/16
CPC分类号: C07D401/12
摘要: A process for preparing pure omeprazole Form B, and compositions containing omeprazole Form B.
摘要翻译: 制备纯奥美拉唑B型的组合物和含奥美拉唑B型的组合物。
-
公开(公告)号:US20080167325A1
公开(公告)日:2008-07-10
申请号:US11963946
申请日:2007-12-24
IPC分类号: A61K31/522 , C07D473/30 , A61P31/12
CPC分类号: A61K31/522 , A61K9/2009 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/2059 , A61K9/48
摘要: Solid pharmaceutical compositions of valacyclovir or pharmaceutically acceptable salts thereof. Embodiments of the invention relate to processes for preparing solid pharmaceutical compositions, avoiding a wet granulation step.
摘要翻译: 伐昔洛韦的固体药物组合物或其药学上可接受的盐。 本发明的实施方案涉及制备固体药物组合物的方法,避免湿法制粒步骤。
-
公开(公告)号:US20100129310A1
公开(公告)日:2010-05-27
申请号:US11573505
申请日:2005-08-08
申请人: Pavak Rajnikanth Mehta , Indu Bushan , Vijay Dinanathji Nasare , Mailatur Sivaraman Mohan , Rahul Sudhakar Gawande , Ravinder Kodipyaka
发明人: Pavak Rajnikanth Mehta , Indu Bushan , Vijay Dinanathji Nasare , Mailatur Sivaraman Mohan , Rahul Sudhakar Gawande , Ravinder Kodipyaka
IPC分类号: A61K31/444 , B01J41/12
CPC分类号: A61K31/473
摘要: Stabilized desloratadine-containing pharmaceutical compositions are prepared using complexes formed by combining desloratadine and a resin in the acidic form.
摘要翻译: 使用通过组合地氯雷他定和酸性形式的树脂形成的络合物来制备含有去氯雷他定的药物组合物。
-
公开(公告)号:US20090124657A1
公开(公告)日:2009-05-14
申请号:US12191611
申请日:2008-08-14
申请人: Ramesh Kappala , Basety Srikanth , Rahul Sudhakar Gawande , Subhash Pandurang Gore , Irukulla Srinivas , Indu Bhushan , Mailatur Sivaraman Mohan
发明人: Ramesh Kappala , Basety Srikanth , Rahul Sudhakar Gawande , Subhash Pandurang Gore , Irukulla Srinivas , Indu Bhushan , Mailatur Sivaraman Mohan
CPC分类号: A61K9/2018 , A61K9/0056
摘要: Pharmaceutical compositions comprising montelukast or pharmaceutically acceptable salts, solvates, polymorphs, enantiomers or mixtures thereof.
摘要翻译: 包含孟鲁司特或其药学上可接受的盐,溶剂合物,多晶型物,对映体或其混合物的药物组合物。
-
公开(公告)号:US20070202162A1
公开(公告)日:2007-08-30
申请号:US11678073
申请日:2007-02-23
申请人: Anand Sankarnarayanan , Subhash Pandurang Gore , Ravinder Kodipyaka , Indu Bhushan , Mailatur Sivaraman Mohan
发明人: Anand Sankarnarayanan , Subhash Pandurang Gore , Ravinder Kodipyaka , Indu Bhushan , Mailatur Sivaraman Mohan
IPC分类号: A61K9/54 , A61K31/717 , A61K9/14 , A61K9/52
CPC分类号: A61K9/5084 , A61K9/2077 , A61K31/717
摘要: The present invention relates to extended release pharmaceutical compositions comprising a beta-blocker drug or a pharmaceutically acceptable salt thereof, wherein said composition comprises at least two extended release portions, each portion having an in vitro dissolution profile that is different from another portion.
摘要翻译: 本发明涉及包含β-阻滞剂药物或其药学上可接受的盐的延长释放药物组合物,其中所述组合物包含至少两个延长释放部分,每个部分具有不同于另一部分的体外溶出曲线。
-
7.Pharmaceutical Compositions Comprising Amorphous Benzimidazole Compounds 审中-公开
标题翻译: 包含无定形苯并咪唑化合物的药物组合物公开(公告)号:US20080146615A1
公开(公告)日:2008-06-19
申请号:US11722247
申请日:2005-12-20
IPC分类号: A61K31/4439 , A61K31/4184
CPC分类号: C07D401/12 , A61K9/5078 , A61K9/5089 , A61K31/4184 , A61K31/4439
摘要: Compositions comprising amorphous substituted benzimidazole compounds.
摘要翻译: 包含非晶取代的苯并咪唑化合物的组合物。
-
公开(公告)号:US20080139609A1
公开(公告)日:2008-06-12
申请号:US11936140
申请日:2007-11-07
IPC分类号: A61K31/439
CPC分类号: A61K31/439 , A61K9/2018 , A61K9/2054 , A61K9/2059 , A61K9/2077 , A61K47/02 , A61K47/10 , A61K47/12
摘要: Stable liquid pharmaceutical compositions comprise granisetron or a pharmaceutically acceptable salt thereof.
摘要翻译: 稳定的液体药物组合物包含格拉司琼或其药学上可接受的盐。
-
9.PHARMACEUTICAL COMPOSITIONS COMPRISING AMORPHOUS BENZIMIDAZOLE COMPOUNDS 审中-公开
标题翻译: 包含不定性苯并咪唑化合物的药物组合物公开(公告)号:US20090324728A1
公开(公告)日:2009-12-31
申请号:US12553409
申请日:2009-09-03
IPC分类号: A61K9/14 , A61K31/435
CPC分类号: C07D401/12 , A61K9/5078 , A61K9/5089 , A61K31/4184 , A61K31/4439
摘要: Compositions comprising amorphous substituted benzimidazole compounds.
摘要翻译: 包含非晶取代的苯并咪唑化合物的组合物。
-
公开(公告)号:US20080193524A1
公开(公告)日:2008-08-14
申请号:US11997044
申请日:2006-07-28
IPC分类号: A61K9/48 , A61K9/30 , A61K31/135
CPC分类号: A61K9/2866 , A61K9/2846 , A61K9/4808 , A61K9/5026 , A61K9/5047 , C09D101/02 , C09D101/28
摘要: The invention relates to extended release pharmaceutical compositions of venlafaxine or pharmaceutically acceptable salts. More particularly this invention relates to a pharmaceutical composition having a core comprising venlafaxine and a coating thereupon. The coating utilizes at least one water insoluble polymer and at least one polymer having pH dependent solubility to delay and modulate the release of the drug in an extended manner.
摘要翻译: 本发明涉及文拉法辛或其药学上可接受的盐的延长释放药物组合物。 更具体地说,本发明涉及具有核心的药物组合物,其中包括文拉法辛及其上的涂层。 该涂层利用至少一种水不溶性聚合物和至少一种具有pH依赖性溶解度的聚合物以延长的方式延迟和调节药物的释放。
-
-
-
-
-
-
-
-
-